Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'

被引:31
|
作者
Lee, Kyu-Sung [12 ]
Lee, Hye Won [12 ]
Choo, Myung-Soo [11 ]
Paick, Jae-Seung [10 ]
Lee, Jeong Gu [9 ]
Seo, Ju Tae [8 ]
Lee, Jeong Zoo [2 ]
Lee, Young-Suk [12 ]
Yoon, Hana [7 ]
Park, Choal Hee [3 ]
Na, Yong-Gil [4 ]
Jeong, Young Beom [5 ]
Lee, Jong Bouk [1 ]
Park, Won Hee [6 ]
机构
[1] Natl Med Ctr, Seoul, South Korea
[2] Pusan Natl Univ, Coll Med, Pusan 609735, South Korea
[3] Keimyung Univ, Sch Med, Taegu, South Korea
[4] Chungnam Natl Univ, Coll Med, Taejon, South Korea
[5] Chonbuk Natl Univ, Sch Med, Jeonju, South Korea
[6] Inha Univ, Coll Med, Inchon, South Korea
[7] Ewha Womans Univ, Sch Med, Seoul, South Korea
[8] Kwandong Univ, Coll Med, Seoul, South Korea
[9] Korea Univ, Coll Med, Seoul 136705, South Korea
[10] Seoul Natl Univ, Coll Med, Seoul, South Korea
[11] Univ Ulsan, Coll Med, Seoul, South Korea
[12] Sungkyunkwan Univ, Dept Urol, Samsung Med Ctr, Sch Med, Seoul, South Korea
关键词
overactive bladder; urinary urgency; propiverine hydrochloride; randomized trial; DOUBLE-BLIND; INCONTINENCE; SYMPTOMS; TOLERABILITY; TOLTERODINE; SOLIFENACIN; PERCEPTION; EFFICACY; TRIAL;
D O I
10.1111/j.1464-410X.2009.09050.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate the effects of a daily regimen of propiverine 20 mg in patients with an overactive bladder (OAB), focused on improving urgency, as the clinical efficacy of treatment for OAB should be measured in terms of urgency, the cornerstone symptom of OAB. PATIENTS AND METHODS Eligible patients aged >= 18 years with symptoms of OAB were enrolled in this multicentre, prospective, parallel, double-blind, placebo-controlled trial. Of 264 patients (mean age 52.2 years), 221 who had efficacy data available from baseline and at least one on-treatment visit with > 75% compliance with medication were analysed (142 in the propiverine group and 79 in the placebo group). All patients were randomized to receive a placebo or 20 mg propiverine once daily in a 12-week study. They completed a 3-day voiding diary before visits during the study period, including the severity of urgency associated with every voiding, using the Indevus Urgency Severity Scale and the Urgency Perception Score. The patients' overall self-evaluation of treatment benefits at the end of the study, and safety data, were also collected. RESULTS The daily urgency episodes reduced significantly from baseline to 12 weeks on propiverine treatment, compared with placebo (-46.0% vs -31.3%, P = 0.005). Secondary endpoints, including sum of urgency severity per 24 h, urgency severity per void, and daytime voiding frequency, were also improved significantly in the propiverine group. Overall, of those patients treated with propiverine, 38.7% rated their treatment as providing 'much benefit', compared with 15.2% of the placebo group (P = 0.025). Adverse events reported by 32 (22.5%) and 10 (12.7%) patients in the propiverine and placebo group were all tolerable. However, this is a short-term study using only one fixed regimen. CONCLUSIONS Propiverine 20 mg once-daily could be an effective treatment for patients with OAB, by improving urgency.
引用
收藏
页码:1565 / 1570
页数:6
相关论文
共 50 条
  • [41] Urgency Severity Scale Could Predict Urodynamic Detrusor Overactivity in Patients With Overactive Bladder Syndrome
    Chung, Shiu-Dong
    Liao, Chun-Hou
    Chen, Yi-Chou
    Kuo, Hann-Chorng
    NEUROUROLOGY AND URODYNAMICS, 2011, 30 (07) : 1300 - 1304
  • [42] Considerations for the management of urgency symptoms in patients with overactive bladder syndrome
    Linda D. Cardozo
    Philip E. V. A. Van Kerrebroeck
    David R. Staskin
    World Journal of Urology, 2009, 27 : 755 - 763
  • [43] Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder
    Karin S. Coyne
    Chris C. Sexton
    Christine Thompson
    Tamara Bavendam
    Linda Brubaker
    International Urogynecology Journal, 2015, 26 : 373 - 382
  • [44] Propiverine A Review of its Use in the Treatment of Adults and Children with Overactive Bladder Associated with Idiopathic or Neurogenic Detrusor Overactivity, and in Men with Lower Urinary Tract Symptoms
    McKeage, Kate
    CLINICAL DRUG INVESTIGATION, 2013, 33 (01) : 71 - 91
  • [45] Efficacy and Safety of Propiverine Hydrochloride for Overactive Bladder in Adult: a Systematic Review and Meta-analysis
    Huang, Wei
    Zong, Huantao
    Zhou, Xin
    Wang, Tao
    Zhang, Yong
    INDIAN JOURNAL OF SURGERY, 2015, 77 : S1369 - S1377
  • [46] Propiverine hydrochloride immediate and extended release:: Comparison of efficacy and tolerability in patients with overactive bladder
    Juenemann, K.-P.
    Hessdoerfer, E.
    Unamba-Oparah, I.
    Berse, M.
    Bruenjes, R.
    Madersbacher, H.
    Gramatte, T.
    UROLOGIA INTERNATIONALIS, 2006, 77 (04) : 334 - 339
  • [47] Urgency and pain in patients with overactive bladder and bladder pain syndrome. What are the differences?
    Castro-Diaz, D.
    Cardozo, L.
    Chapple, C. R.
    Espuna, M.
    Kelleher, C.
    Kirby, M.
    Milsom, I.
    Sievert, K-D
    Tubaro, A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (03) : 356 - 362
  • [48] Strong Correlation Between the Overactive Bladder Symptom Score and Urgency Severity Score in Assessment of Patients With Overactive Bladder Syndrome
    Ke, Qian-Sheng
    Kuo, Hann-Chorng
    TZU CHI MEDICAL JOURNAL, 2010, 22 (02): : 82 - 86
  • [49] Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder
    Leng, Jing
    Liao, Limin
    Wan, Ben
    Du, Chuanjun
    Li, Wei
    Xie, Keji
    Shen, Zhoujun
    Xu, Zhuoqun
    Wu, Shiliang
    Fang, Zujun
    Ma, Lulin
    Han, Shaomei
    Feustel, Cornelia
    Yang, Yong
    Madersbacher, Helmut
    BJU INTERNATIONAL, 2017, 119 (01) : 148 - 157
  • [50] The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects
    Chapple, CR
    Artibani, W
    Cardozo, LD
    Castro-Diaz, D
    Craggs, M
    Haab, F
    Khullar, V
    Versi, E
    BJU INTERNATIONAL, 2005, 95 (03) : 335 - 340